Investors

Investors

Corporate Profile

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.

The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of first-line triple-negative breast cancer. An investigator-sponsored Phase 2 study in second-line acute lymphoblastic leukemia is ongoing in the Nordic countries of Europe.

ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States at its recently opened GMP manufacturing site in Princeton, New Jersey, USA.

Stock Quote

Exchange
Price
Change (%)
Volume
Data as of
Exchange
Price
Change (%)
Volume
Data as of
More >>

Recent News

Date Title and Summary Additional Formats
Toggle Summary ERYTECH Provides Business Update and Reports Financial Results for the First Quarter of 2021
ERYTECH Provides Business Update and Reports Financial Results for the First Quarter of 20 2 1 Conference call and webcast on Wednesday, May 5, 2021 at 8:30am EST/ 2:30pm CET          TRY b eCA-1, Phase 3 clinical trial in 2 n d line pancreatic cancer, fully enrolled, and on track for final results
View HTML
Toggle Summary ERYTECH Announces $30.0 Million Registered Direct Offering
ERYTECH Announces $ 30.0 Million Registered Direct Offering Lyon (France) and Cambridge, MA (U.S.), April 2 9 , 202 1 – ERYTECH Pharma (Nasdaq & Euronext:   ERYP) (the “Company”) , a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug
View HTML
Toggle Summary ERYTECH Reports Cash Balance at End of Q1 2021 and Announces the Details of its 2021 Q1 conference call
ERYTECH Reports Cash Balance at End of Q1 202 1 and Announces the Details of its 2021 Q1 conference call Publication of Q1 2021 results on 4 May 2021 after market close Lyon (France) and Cambridge, MA (U.S.), April 2 9 , 202 1 – ERYTECH Pharma (Nasdaq & Euronext:   ERYP), a clinical-stage
View HTML
Toggle Summary ERYTECH Requested a Pre-BLA Meeting with the FDA to Discuss Path to Approval in ALL
ERYTECH Requested a Pre-BLA Meeting with the FDA to Discuss Path to Approval in ALL ERYTECH invited by FDA to request a pre-BLA meeting F irst step in the marketing approval process with the FDA for eryaspase for the treatment of hypersensitive ALL patients based on the positive results of the
View HTML
More >>

Upcoming Events

Date Event Details
Summary Toggle Sep 21, 2021 at 8:30 AM EDT

Erytech Pharma 2nd Quarter of 2021 Conference Call and Webcast

A press release will be sent the day before.
Summary Toggle Nov 16, 2021 at 8:30 AM EST

Erytech Pharma 3rd Quarter of 2021 Conference Call and Webcast

A press release will be sent the day before.

RECEIVE E-MAIL ALERTS

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Top